Tetra Bio Pharma Inc (TBP)

0.0300
+0.0050(+20.00%)
  • Volume:
    669,965
  • Bid/Ask:
    0.0250/0.0300
  • Day's Range:
    0.0250 - 0.0300

TBP Overview

Prev. Close
0.025
Day's Range
0.025-0.03
Revenue
-
Open
0.025
52 wk Range
0.015-0.18
EPS
-0.092
Volume
669,965
Market Cap
13.72M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,057,353
P/E Ratio
-0.326
Beta
2.09
1-Year Change
-79.31%
Shares Outstanding
457,300,771
Next Earnings Date
Feb 27, 2023
What is your sentiment on Tetra Bio Pharma?
or
Market is currently closed. Voting is open during market hours.

Tetra Bio Pharma Inc News

  • Energy stocks drag down TSX
    • ByReuters-

    (Reuters) - Canada's main stock index fell on Tuesday, dragged down by energy stocks as the rapid spread of COVID-19 infections in India raised concerns about oil demand. * The...

  • TSX edges higher on energy boost
    • ByReuters-

    May 4 (Reuters) - Canada's main stock index rose on Tuesday, helped by energy stocks as crude prices gained on optimism over fuel demand, although data showing the country's C$1.1...

Tetra Bio Pharma Inc Analysis

Tetra Bio Pharma Inc Company Profile

Tetra Bio Pharma Inc Company Profile

Employees
33
Market
Canada
  • Type:Equity
  • Market:Canada
  • ISIN:CA88166Y1007
  • CUSIP:88166Y100

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuyStrong Sell
Technical IndicatorsStrong BuyStrong BuyBuySellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Sell
  • Guy Chamberland is a liar, all the promises are missed out, no approvals ,no products ,no share value. he is making TBP a salary generating company thats it.
    0
    • what happen to this?any one have an idea.
      0
      • what happen to this?any one have an idea.
        0
        • Quebec just invested 5 million$ , its a buy at this level.
          0
          • Quebec just invested 5 million$ , its a buy at this level.
            0
            • Save ur money amd stay away from this one
              0
              • Let the good times roll
                0
                • Ya !! good news for Tetra Bio
                  0
                  • Yessss
                    0
                • Cash flows from operating activities - continuing operations (11,612,825)
                  0
                  • Good News for ADRS-003: Based on the safety data, the medicinal ingredient and the sterile injectable drug product ARDS-003 are both safe for use in humans
                    0